What You Should Know:
– Implicity, a leader in remote patient monitoring and cardiac data management, has received FDA 510(k) clearance for SignalHF1, a groundbreaking new algorithm within their remote monitoring solution.
– SignalHF1 algorithm empowers early detection and intervention, paving the way for improved patient outcomes and a brighter future for cardiac care.
Leveraging Big Data for Better Heart Care
Implicity holds a unique distinction as the first private company to access the Health Data Hub, a vast repository of patient data on heart disease. By combining this comprehensive database with data from their AI-powered platform, Implicity’s team developed and validated SignalHF1. This machine learning algorithm analyzes data to assess a patient’s risk of future heart failure events, enabling early intervention.
Making a Difference for All Patients
SignalHF1 stands out for its versatility. Unlike device-specific solutions, it can analyze data from various Cardiac Implantable Electronic Devices (CIEDs) – including pacemakers, defibrillators, and cardiac resynchronization therapy devices – manufactured by leading companies like Biotronik, Boston Scientific, and Medtronic. Notably, SignalHF1 is the first pacemaker-compatible heart failure algorithm available.
Early Detection, Timely Intervention
The algorithm’s strength lies in its ability to identify subtle trends that might indicate a worsening patient condition. Care teams receive automatic alerts when a patient’s risk score surpasses a predefined threshold, signifying a heightened risk of heart failure and potential hospitalization. This allows for timely intervention and preventive measures.
Implicity: A Leader in Remote Cardiac Care
Implicity’s remote monitoring platform empowers Independent Diagnostic Testing Facilities and cardiac electrophysiology centers to deliver exceptional care to patients with implanted cardiac devices. Their platform provides:
- Device-Agnostic Data Aggregation: Seamless data collection and standardization from any implantable cardiac device, regardless of manufacturer.
- Advanced AI Development: Ongoing research and development on AI-based algorithms focused on improved patient care and preventive medicine advancements.
“Heart failure remains a significant healthcare challenge, contributing to approximately one million hospitalizations each year. Preventing even a portion of these would be a game-changer in cardiac care,” said Dr. Arnaud Rosier, Implicity’s CEO and cardiologist. “SignalHF is an innovative and effective tool that physicians can use to assess risk of hospitalization due to heart failure earlier, enabling interventions that can lead to better outcomes and reduce hospital admissions.”
